Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Human ovarian carcinoma exhibits a spectrum of responses to treatment with cisplatin, ranging from marked sensitivity to relative resistance. Variations in the efficiency with which cells repair cisplatin-DNA adducts may in part determine cisplatin sensitivity. We have investigated the use of a novel cell-free assay of nucleotide excision repair of platinated DNA to assess the DNA repair capacity of direct biopsies of untreated human ovarian carcinoma. In this pilot study, ovarian carcinoma extracts performed in vitro excision repair of platinated DNA. Moreover, tumors from different individuals varied as much as 10-fold in their repair capacity in this assay.

Original publication

DOI

10.1002/ijc.2910590317

Type

Journal article

Journal

Int J Cancer

Publication Date

01/11/1994

Volume

59

Pages

388 - 393

Keywords

Animals, CHO Cells, Cell-Free System, Cisplatin, Cricetinae, DNA Adducts, DNA Repair, DNA, Neoplasm, Female, HeLa Cells, Humans, Neoplasm Proteins, Ovarian Neoplasms, Plasmids